IBI310

IBI310 · Innovent Biologics (Suzhou) Co., Ltd.

Drug timelines are a Plus or Pro feature.

11 regulatory and trial events tracked for IBI310, covering 2019-12-19 to 2026-04-16. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. [Phase 2, Phase 3]

See pricing